629 related articles for article (PubMed ID: 29195116)
1. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
2. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
3. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
4. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
7. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
9. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
11. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Wongchenko MJ; Ribas A; Dréno B; Ascierto PA; McArthur GA; Gallo JD; Rooney IA; Hsu J; Koeppen H; Yan Y; Larkin J
Pigment Cell Melanoma Res; 2018 Jul; 31(4):516-522. PubMed ID: 29156488
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
13. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
14. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
20. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
